Related Experiment Video

Updated: Jul 13, 2026

Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
11:01

Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease

Published on: August 30, 2011

The P300 component in patients with Alzheimer's disease and their biological children

Brandon A Ally1, Gary E Jones, Jack A Cole

  • 1Harvard Medical School and New England GRECC, Geriatric Neuropsychology Laboratory, USA. bally@bu.edu

Biological Psychology
|December 13, 2005
PubMed

Insights

The P300 brainwave shows abnormalities in Alzheimer's disease (AD) patients and their children. This suggests P300 may serve as an early indicator for preclinical AD in offspring with a family history of the disease.

Area of Science:

  • Neuroscience
  • Cognitive Science
  • Genetics

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
  • Early detection of AD is crucial for effective management.
  • The P300 event-related potential (ERP) is a cognitive marker that has shown abnormalities in AD patients.

Purpose of the Study:

  • To examine P300 in biological children of AD patients.
  • To assess the utility of P300 as a preclinical marker in offspring at risk for AD.
  • To investigate electrophysiological differences between AD patients, their offspring, and control groups.

Main Methods:

  • The auditory oddball paradigm was used to elicit P300.
  • Participants included an AD group, their biological children (FH+ group), and two control groups.
  • ERPs were recorded from Fz, Cz, and Pz sites and analyzed using ANOVA.

Main Results:

  • P300 amplitudes were significantly reduced in the AD group compared to controls.
  • Both P300 amplitude and latency were significantly impaired in the FH+ group compared to their matched controls.
  • These findings indicate electrophysiological alterations in individuals with a family history of AD.

Conclusions:

  • The study confirms P300 amplitude abnormalities in AD patients.
  • Individuals with a family history of AD exhibit potential preclinical electrophysiological evidence of the disease.
  • P300 may serve as a valuable preclinical biomarker for identifying individuals at risk for AD.
Abstract

More Related Videos

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease09:38

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration04:41

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration

Published on: January 9, 2020

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...